Keftragard 500mg/250mg Injection
Marketer
Ipca Laboratories Ltd
Salt Composition
Ceftriaxone (500mg) + Sulbactam (250mg)
Overview Keftragard 500mg/250mg Injection
Ceftibuten/Sulbactam 500mg/250mg Injection is a dual-action antibiotic. It's indicated for a range of bacterial infections, inhibiting microbial proliferation and preventing infection spread. Administration must be under a doctor's direct supervision. Consistent adherence to the prescribed dosage schedule is crucial; completing the full course is vital, regardless of symptom improvement. Premature cessation can compromise efficacy. Typical side effects include nausea, vomiting, diarrhea, and dyspepsia. Worsening side effects warrant immediate medical attention. Seek immediate emergency care for allergic reactions (e.g., rash, pruritus, edema, dyspnea). Inform your physician about all current medications before starting this treatment. Pregnant or lactating individuals should consult their doctor prior to use. Alcohol consumption should be avoided due to potential increased drowsiness. While typically non-impairing, driving should be avoided if drowsiness or dizziness occur. Adequate rest, a nutritious diet, and ample hydration are recommended for optimal recovery. Your doctor may order blood tests and other diagnostics to monitor treatment response.
Uses of Keftragard 500mg/250mg Injection
Infections caused by bacteria
Major Benefits of Keftragard 500mg/250mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Keftragard 500mg/250mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Keftragard 500mg/250mg Injection:
Administering this medication will be handled by your physician or registered nurse; self-medication is strictly prohibited.
How Keftragard 500mg/250mg Injection works:
The injectable formulation Keftragard (500mg Ceftriaxone/250mg Sulbactam) unites two active agents. Ceftriaxone, a third-generation cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering bacterial growth and survival. Sulbactam, a beta-lactamase inhibitor, counteracts bacterial resistance mechanisms, thus boosting Ceftriaxone's efficacy.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions associated with the concomitant use of alcohol and Keftragard 500mg/250mg Injection.
PregnancySAFE IF PRESCRIBED
The injectable medication Keftragard, 500mg/250mg, is typically deemed safe for pregnant individuals. Preclinical trials using animals revealed minimal or absent negative impacts on fetal development; yet, data from human clinical trials remains scarce.
Breast feedingCAUTION
Administering Keftragard 500mg/250mg Injection to breastfeeding mothers requires careful consideration. Mothers should discontinue breastfeeding for the duration of treatment and until the medication is fully cleared from their system.
DrivingUNSAFE
Administering Keftragard 500mg/250mg Injection may induce drowsiness, blurred vision, or dizziness. Refrain from operating a vehicle should these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data regarding Keftragard 500mg/250mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
The 500mg/250mg Keftragard Injection requires careful administration in individuals with severe hepatic impairment; dosage modification may be necessary. Patients should seek medical advice. Dosage alteration for the 500mg/250mg Keftragard Injection is unnecessary for those with mild to moderate liver dysfunction.
What if you forget to take Keftragard 500mg/250mg Injection :
Should you inadvertently skip a Keftragard 500mg/250mg Injection, seek your physician's advice.
Facts to Know About Keftragard 500mg/250mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-Infective Agents |
3,018 People bought this recently